Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Aggrecan Antibody (MK-302), Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP2296700.025ML
Description
Aggrecan Monoclonal specifically detects Aggrecan in Human, Mouse, Rat, Bovine, Canine, Rabbit, Sheep samples. It is validated for Western Blot, ELISA, Radioimmunoassay.Specifications
Aggrecan | |
Monoclonal | |
Unconjugated | |
Ascites with No Preservative | |
AGC1SEDK, aggrecan, aggrecan core protein, Cartilage-specific proteoglycan core protein, Chondroitin sulfate proteoglycan 1, Chondroitin sulfate proteoglycan core protein 1, CSPCP, CSPG1aggrecan 1, CSPGCP, large aggregating proteoglycan, MSK16AGCAN | |
Mouse | |
Unpurified | |
RUO | |
Primary | |
Reacts with a wide range of cartilage proteoglycans after either chondroitinase (ABC or AC) or testicular hyaluronidase digestion. Native proteoglycans do not react with MAB2035. Antibody binding to epitope is successfully inhibited by disaccharides of chondroitin-6-sulfate. Recognizes the chondroitin-6-sulfate stubs (preferentially in clusters) of high density cartilage proteoglycans of different species. No cross-reactivity with dermatan sulfate, keratan sulfate or chondroitin-4-sulfate. | |
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. | |
IgG1 |
ELISA, Western Blot, Radioimmune Assays (RIA) | |
MK-302 | |
Western Blot 1:100-1:2000, ELISA 1:100-1:5000, Radioimmunoassay 1:100-1:200 | |
P16112 | |
ACAN | |
Chondroitinase ABC-digested adult human aggrecan. | |
0.025 mL | |
Extracellular Matrix, Growth and Development, Mesenchymal Stem Cell Markers, Neuronal Cell Markers, Neuronal Stem Cell Markers, Stem Cell Markers | |
176 | |
Rat, Human, Sheep, Canine, Rabbit, Bovine, Mouse | |
Ascites |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction